Biotech, Healthcare & Pharmaceutical
Virtual Conference

Wednesday, October 13, 2010

The conference will focus on key companies throughout the Biotech, Healthcare & Pharma Industry.

Aradigm
Aradigm is actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease.

Since 1991, the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products. This team pioneered the AERx iDMS pulmonary delivery of insulin that was used in Phase 3 clinical trials conducted by its partner Novo Nordisk. With the depth of experience and expertise in inhalation delivery, Aradigm is uniquely positioned to develop a portfolio of its own products to treat patients with severe respiratory diseases. The current pipeline includes products that are being developed by Aradigm, or in partnerships with others, for the treatment of cystic fibrosis, bronchiectasis* and inhalation anthrax. The company is also investigating the use of its technology for tobacco smoking cessation therapy.

Hana Biosciences, Inc.
Hana Biosciences, Inc. is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture.

Ophthalmic Imaging Systems Inc.
Ophthalmic Imaging Systems has been the leading provider of ophthalmic imaging and informatics solutions since 1984. Our industry-leading OIS Symphony™ and WinStation product lines have delivered the ability to view all of a practice's ophthalmic images and diagnostic reports side-by-side automatically; producing unprecedented gains in both practice efficiency and quality of care.

ImmunoCellular Therapeutics
We are a clinical-stage company that is focused on developing new therapeutics to fight cancer using the immune system. Our product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. Our main disease focus using our immunotherapy technologies is to treat glioblastoma, but these therapies may also be applicable to multiple other cancers such as pancreatic, colon and breast cancers due to presence of similar epitopes on these malignant cells. Our antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer.

Our primary focus is on the development of a therapeutic vaccine targeting cancer stem cells for multiple cancer indications, and we expect to file an Investigational New Drug (IND) application in the third quarter of 2009 to begin a Phase 1 clinical trial. We have an exclusive worldwide license from Cedars-Sinai Medical Center for our immunotherapy technologies as well as cancer stem cell technologies.

CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine. A pivotal Phase III clinical trial with Multikine in newly diagnosed and yet untreated head and neck cancer is expected to start towards the end of 2010. In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33 percent at a median of three and a half years following surgery. CEL-SCI is also developing a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform and an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com. (Apricus Bio was previously named NexMed, Inc. The corporate name was changed in September 2010 in recognition of the evolution and expansion of the Company's business.)

Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed exclusively in the U.S. by Inverness Medical Innovations, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and Chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform (DPP®) technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.